ClinicalTrials.gg
CompletedNCT01558739MACS2030Updated Mar 3, 2015Results posted

Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

A Phase 4 interventional study of INC424 in Primary Myelofibrosis (PMF), Post Polycythaemia Myelofibrosis (PPV MF) and Post Essential Thrombocythaemia Myelofibrosis (PET-MF), sponsored by Novartis Pharmaceuticals. Completed at 10 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-03.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.

Enrollment
24th of 50
48 · median 45
Started
2012
with 1 other
Phase 4
4 of 50
1 open now
Registered
12th of 50
by date
Lead sponsor
11 of 50
Novartis Pharmaceuticals

Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 24th largest by enrollment, is one of 2 that started in 2012, is one of 4 in phase 4, and was the 12th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 101 Primary Myelofibrosis studies recruiting now, 83 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing ruxolitinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of INC424 in patients with PMF, PPV MF, or PET-MF using a composite measure of either an objective endpoint (> 50% reduction in splenomegaly using palpitation at 48 weeks) and/or a subjective endpoint (>50% reduction in total symptom score at 48 weeks).

03

Conditions studied

  • Primary Myelofibrosis (PMF)
  • Post Polycythaemia Myelofibrosis (PPV MF)
  • Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

Keywords

  • Ruxolitinib
  • INC424
  • myelofibrosis
  • PMF
  • post polycythemia myelofibrosis
  • PPV MF
  • post-essential thrombocythemia myelofibrosis
  • PET-MF
  • Primary Myelofibrosis
  • Polycythemia
  • Thrombocythemia
  • Essential Thrombocytosis
  • myeloproliferative Disorders
  • Bone Marrow Diseases
  • Haematologic Diseases
  • Blood Coagulation Disorders
  • Blood Platelet Disorders
  • Haemorrhagic Disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must not be eligible for another ongoing INC424 clinical trial.
  • Patients must be diagnosed with PMF, PPV MF or PET-MF, according to the 2008 revised World Health Organization criteria irrespective of JAK2 mutation status.
  • Patients with PMF requiring therapy must be classified as high risk (3 prognostic factors) OR intermediate risk level 2 (2 prognostic factors, no more), OR intermediate risk level 1 (1 prognostic factor, no more) with an enlarged spleen. The prognostic factors, defined by the International Working Group are:

    1. Age > 65 years;
    2. Presence of constitutional symptoms (weight loss, fever, night sweats); marked anemia ( \< 10g/dL)*;
    3. Leukocytosis (history of WBC > 25 x109/L);
    4. Circulating blasts > 1%. • A hemoglobin value \< 10 g/dL must be demonstrated during the Screening Visit for patients who are not transfusion dependent. Patients receiving regular transfusions of packed red blood cells will be considered to have hemoglobin \< 10 g/dL for the purpose of evaluation of risk factors.
  • Patients with Intermediate-1 disease and splenomegaly must have a palpable spleen measuring 5 cm or greater from the costal margin to the point of greatest splenic protrusion.
  • Patients must have a peripheral blood blast count of \< 10%.
  • Patients with adequate liver function defined as direct ≤ 2.0 x and ≤ 2.5 x ULN.
  • Patients with adequate renal function defined as serum creatinine ≤ 2 x ULN.
  • Patients with an performance status of 0, 1, or 2 (Appendix 5).

Exclusion criteria

Exclusion criteria:

  • Patients eligible for hematopoietic stem cell transplantation (suitable candidate and a suitable donor is available).
  • Patients with history of in past 3 years except for treated, early-stage squamous or basal cell carcinoma in situ.
  • Patients undergoing treatment with hematopoietic growth factor receptor agonists (i.e., erythropoietin [Epo], granulocyte colony stimulating factor (GCSF [Neupogen; Neulasta], romiplostim, eltrombopag) at any time within 2 weeks prior to Screening or 4 weeks prior to Baseline.
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral INC424 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection).
  • Patients with cardiac disease which in the Investigator's opinion may jeopardize the safety of the patient or the compliance with the protocol.
  • Patients with bacterial, fungal, parasitic or viral infection which require therapy. Patients with acute bacterial infections requiring antibiotic use should delay screening/enrollment until the course of antibiotic therapy has been completed.
  • Patients with known active hepatitis A, B, C or who are -positive.
  • Patients with inadequate bone marrow reserve as demonstrated by:

    1. (ANC) that is ≤ 1000/µL.
    2. count that is \< 100,000/µL without the assistance of growth factors, thrombopoietic factors or platelet transfusions.
  • Patients with any history of platelet counts \< 50,000/µL or ANC \< 500/µL except during treatment for a myeloproliferative disorder or treatment with cytotoxic therapy for any other reason.
  • Patients with coagulation parameters (PT, , INR) ≥ 1.5.
  • Patients with known to INC424 or other JAK1/2 inhibitors, or to their .
  • Patients under ongoing treatment with another medication or having been treated with an investigational medication within 30 days of screening.
  • Patients with any concurrent condition that, in the Investigator's opinion would jeopardize the safety of the patient or compliance with the protocol.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    INC424

    Patients diagnosed with PMF, PPV MF, or PET-MF were treated with oral INC424 at a dose of 15 - 20 mg (dose based on Baseline platelet count) twice daily.

    Drug: INC424

Interventions

  • DrugINC424

    Ruxolitinib was provided in 5 mg tablets, packaged in bottles. 15 - 20 mg (dose based on Baseline platelet count) twice daily.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment Success

    Treatment success was defined as a 50% or greater reduction in palpable spleen length versus baseline at 48 weeks and/or a 50% or greater improvement in total symptom score (derived from the MF symptom assessment form (MFSAF) questionnaire) versus baseline at the week 48 time point. The MFSAF assesses the following symptoms (all scored from absent (0) to worst imaginable (10)): general fatigue, abdominal pain (and discomfort), inactivity (ability to move and walk around), cough, night sweats, itching (pruritus), bone pain (diffuse not joint pain or arthritis), fever, change in appetite/unintentional weight loss (or gain) in past 6 months, overall quality of life (QoL).

    Time frame: 48 Weeks

Secondary outcomes

  1. Percentage of Participants With Best Overall Response

    Response to treatment and disease progression was assessed by physical examination, specifically assessing changes in spleen size by palpation. Disease response and progression was evaluated using the International Working Group for myelofibrosis Research and Treatment Response Criteria.

    Time frame: week 48

  2. Change From Baseline in Myelofibrosis Symptoms Assessment Form (MF-SAF)

    The MF-SAF consists of seven questions about key symptoms and impact of MF. Questions are scored on a scale of 0-10, with higher scores indicating more severe symptoms and greater inactivity. Questions 1-6, which together comprise a Total Symptom Score (TSS), investigate the following symptoms: night sweats, pruritus/itching, abdominal discomfort, pain under the ribs, early satiety and bone/muscle pain. Question 7 asks patients to report levels of inactivity. The TSS reflects the sum of the scores of these symptoms excluding inactivity, with the maximum possible score being 60 (most severe symptom experienced).

    Time frame: Baseline, week 4, week 12, week 24, week 48

  3. Change From Baseline in EQ5D Preference Index (5 Level EuroQol Questionnaire Determining Quality of Life) From Baseline

    The EQ-5D is a standardized instrument used for measuring health outcomes in a wide range of health conditions and treatment. It consists of a descriptive system and a visual analogue scale (EQ-VAS). The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The EQ-VAS records the participant's self-rated health on a vertical, VAS where the endpoints are labeled 'best imaginable health state' and 'worst imaginable health state'. The EQ-5D health state was converted to a single summary index by applying a formula that attaches a weight to each of the levels in each dimension. The final EQ5D preference index scores range from 0 to 1 with higher scores indicating better health.

    Time frame: Baseline, week 4, week 12, week 24, week 48

  4. Number of Hospitalizations

    Medical resource utilization (MRU) was assessed according to the number of hospitalizations.

    Time frame: week 12, week 24, week 26, week 48

  5. Duration of Hospitalizations

    MRU was assessed according to the mean duration of hospitalization visits.

    Time frame: week 48

  6. Number of Accident & Emergency Visits From Baseline

    MRU was assessed according to the number of accidents and emergency room visits.

    Time frame: baseline to week 12, week 12 to week 24, week 24 to week 36, week 36 to week 48

  7. Number of General Practitioner (GP), Specialists' and Urgent Care Visits

    MRU was assessed according to the number of GP, specialists', and urgent care visits.

    Time frame: baseline to week 12, week 12 to, week 24, week 24 to week 36, week 36 to week 48

  8. Percentage of Participants With Transfusion Dependency Status

    Transfusion dependency status from baseline through the end of study was assessed. New onset of transfusion dependency was defined as the use of 2 or more units of red blood cell products during the 8 weeks prior to a study visit. New onset of transfusion independency was defined as the use of 0 or 1 unit of red blood cell products during the 8 weeks prior to a study visit.

    Time frame: baseline (BL), end of treatment (up to 28 days post last treatment) (EOT)

07

Results

Posted Mar 3, 2015

Participant flow

54 patients were screened. 48 patients were enrolled as planned.

Participant flow — Overall Study
MilestoneINC424
Started48
Completed31
Not completed17
Withdrew: Adverse event7
Withdrew: Withdrawal by subject2
Withdrew: Death3
Withdrew: Disease progression4
Withdrew: Protocol violation1

Outcome measures

PrimaryPercentage of Participants With Treatment Success

Treatment success was defined as a 50% or greater reduction in palpable spleen length versus baseline at 48 weeks and/or a 50% or greater improvement in total symptom score (derived from the MF symptom assessment form (MFSAF) questionnaire) versus baseline at the week 48 time point. The MFSAF assesses the following symptoms (all scored from absent (0) to worst imaginable (10)): general fatigue, abdominal pain (and discomfort), inactivity (ability to move and walk around), cough, night sweats, itching (pruritus), bone pain (diffuse not joint pain or arthritis), fever, change in appetite/unintentional weight loss (or gain) in past 6 months, overall quality of life (QoL).

Time frame:
48 Weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Success
Percentage of participantsINC424
Percentage of Participants With Treatment Success50
SecondaryPercentage of Participants With Best Overall Response

Response to treatment and disease progression was assessed by physical examination, specifically assessing changes in spleen size by palpation. Disease response and progression was evaluated using the International Working Group for myelofibrosis Research and Treatment Response Criteria.

Time frame:
week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Best Overall Response
Percentage of participantsINC424
Clinical improvement6.3
Complete response6.3
Partial response39.6
Stable disease47.9
SecondaryChange From Baseline in Myelofibrosis Symptoms Assessment Form (MF-SAF)

The MF-SAF consists of seven questions about key symptoms and impact of MF. Questions are scored on a scale of 0-10, with higher scores indicating more severe symptoms and greater inactivity. Questions 1-6, which together comprise a Total Symptom Score (TSS), investigate the following symptoms: night sweats, pruritus/itching, abdominal discomfort, pain under the ribs, early satiety and bone/muscle pain. Question 7 asks patients to report levels of inactivity. The TSS reflects the sum of the scores of these symptoms excluding inactivity, with the maximum possible score being 60 (most severe symptom experienced).

Time frame:
Baseline, week 4, week 12, week 24, week 48
Reported as:
Mean · score on a scale
Change From Baseline in Myelofibrosis Symptoms Assessment Form (MF-SAF)
score on a scaleINC424
Week 4 (n=37)-8.78 ± 10.638
Week 12 (n=35)-8.46 ± 12.871
Week 24 (n=30)-9.13 ± 11.950
Week 48 (n=18)-7.83 ± 9.966
SecondaryChange From Baseline in EQ5D Preference Index (5 Level EuroQol Questionnaire Determining Quality of Life) From Baseline

The EQ-5D is a standardized instrument used for measuring health outcomes in a wide range of health conditions and treatment. It consists of a descriptive system and a visual analogue scale (EQ-VAS). The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The EQ-VAS records the participant's self-rated health on a vertical, VAS where the endpoints are labeled 'best imaginable health state' and 'worst imaginable health state'. The EQ-5D health state was converted to a single summary index by applying a formula that attaches a weight to each of the levels in each dimension. The final EQ5D preference index scores range from 0 to 1 with higher scores indicating better health.

Time frame:
Baseline, week 4, week 12, week 24, week 48
Reported as:
Mean · unit on a scale
Change From Baseline in EQ5D Preference Index (5 Level EuroQol Questionnaire Determining Quality of Life) From Baseline
unit on a scaleINC424
week 4 (n=40)0.06 ± 0.173
week 12 (n=38)0.05 ± 0.178
week 24 (n=34)0.05 ± 0.231
week 48 (n=29)0.03 ± 0.222
SecondaryNumber of Hospitalizations

Medical resource utilization (MRU) was assessed according to the number of hospitalizations.

Time frame:
week 12, week 24, week 26, week 48
Reported as:
Mean · number of hospitalizations
Number of Hospitalizations
number of hospitalizationsINC424
week 12 (n=48)0.10 ± 0.371
week 24 (n=40)0.03 ± 0.158
week 36 (n=37)0.05 ± 0.229
week 48 (n=35)0.09 ± 0.284
SecondaryDuration of Hospitalizations

MRU was assessed according to the mean duration of hospitalization visits.

Time frame:
week 48
Reported as:
Mean · days
Duration of Hospitalizations
daysINC424
Duration of Hospitalizations9.00 ± 5.852
SecondaryNumber of Accident & Emergency Visits From Baseline

MRU was assessed according to the number of accidents and emergency room visits.

Time frame:
baseline to week 12, week 12 to week 24, week 24 to week 36, week 36 to week 48
Reported as:
Median · Number of visits
Number of Accident & Emergency Visits From Baseline
Number of visitsINC424
baseline to week 12 (n=48)0.00 ± 0.412
week 12 to week 24 (n=39)0.00 ± 0.160
week 24 to week 36 (n=33)0.00 ± 0.415
week 36 to week 48 (n=33)0.00 ± 0.242
SecondaryNumber of General Practitioner (GP), Specialists' and Urgent Care Visits

MRU was assessed according to the number of GP, specialists', and urgent care visits.

Time frame:
baseline to week 12, week 12 to, week 24, week 24 to week 36, week 36 to week 48
Reported as:
Median · number of visits
Number of General Practitioner (GP), Specialists' and Urgent Care Visits
number of visitsINC424
GP visits, baseline to week 12 (n=45)0.0 (0.0 to 4.0)
GP visits, week 12 to week 24 (n=36)0.0 (0.0 to 1.0)
GP visits, week 24 to week 36 (n=33)0.0 (0.0 to 2.0)
GP visits, week 36 to week 48 (n=33)0.0 (0.0 to 3.0)
Specialists visits, baseline to week 12 (n=47)0.00 (0.0 to 8.0)
Specialists visits, week 12 to week 24 (n=36)0.00 (0.0 to 2.0)
Specialists visits, week 24 to week 36 (n=33)0.00 (0.0 to 4.0)
Specialists visits, week 36 to week 48 (n=33)0.00 (0.0 to 3.0)
Urgent care visits, baseline to week 12 (n=48)0.00 (0.0 to 1.0)
Urgent care visits, week 12 to week 24 (n=39)0.00 (0.0 to 0.0)
Urgent care visits, week 24 to week 36 (n=33)0.00 (0.0 to 1.0)
Urgent care visits, week 36 to week 48 (n=33)0.00 (0.0 to 1.0)
SecondaryPercentage of Participants With Transfusion Dependency Status

Transfusion dependency status from baseline through the end of study was assessed. New onset of transfusion dependency was defined as the use of 2 or more units of red blood cell products during the 8 weeks prior to a study visit. New onset of transfusion independency was defined as the use of 0 or 1 unit of red blood cell products during the 8 weeks prior to a study visit.

Time frame:
baseline (BL), end of treatment (up to 28 days post last treatment) (EOT)
Reported as:
Number · Percentage of participants
Percentage of Participants With Transfusion Dependency Status
Percentage of participantsINC424
From independency at BL to independency at EOT0.0
From dependency at BL to independency at EOT2.1
From missing at BL to independency at EOT0.0
From independency at BL to dependency at EOT0.0
From dependency at BL to dependency at EOT10.4
From missing at BL to dependency at EOT35.4
From independency at BL to missing at EOT0.0
From dependency at BL to missing at EOT0.0
From missing at BL to missing at EOT52.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
INC424—23/48 (47.9%)47/48 (97.9%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventINC424
AnaemiaBlood and lymphatic system disorders3/48
SplenomegalyBlood and lymphatic system disorders2/48
Abdominal painGastrointestinal disorders2/48
Staphylococcal sepsisInfections and infestations2/48
DyspnoeaRespiratory, thoracic and mediastinal disorders2/48
Febrile neutropeniaBlood and lymphatic system disorders1/48
ThrombocytopeniaBlood and lymphatic system disorders1/48
Atrial fibrillationCardiac disorders1/48
CataractEye disorders1/48
Eyelid ptosisEye disorders1/48
Most frequent other events
Showing 10 of 40
Most frequent other events
EventINC424
AnaemiaBlood and lymphatic system disorders20/48
ThrombocytopeniaBlood and lymphatic system disorders17/48
EpistaxisRespiratory, thoracic and mediastinal disorders12/48
Abdominal painGastrointestinal disorders11/48
DiarrhoeaGastrointestinal disorders11/48
FatigueGeneral disorders11/48
ContusionInjury, poisoning and procedural complications11/48
HeadacheNervous system disorders11/48
LethargyNervous system disorders10/48
DizzinessNervous system disorders9/48

Baseline characteristics

All enrolled patients were included in the Full Analysis Set and the Safety Set.

Age, Continuous
Age, Continuous(Years)INC424
Mean69.12 ± 10.419
Sex: Female, Male
Sex: Female, Male(Participants)INC424
Female21
Male27
08

Study locations

10 sites
  • Novartis Investigative Site
    Cardiff, Wales CF14 4XN, United Kingdom
  • Novartis Investigative Site
    Bournemouth, BH7 7DW, United Kingdom
  • Novartis Investigative Site
    East Yorkshire, HU16 5JQ, United Kingdom
  • Novartis Investigative Site
    Edinburgh, EH4 2XU, United Kingdom
  • Novartis Investigative Site
    Leicester, LE7 5WW, United Kingdom
  • Novartis Investigative Site
    Liverpool, L7 8XP, United Kingdom
  • Novartis Investigative Site
    London, SE1 9RT, United Kingdom
  • Novartis Investigative Site
    London, W12 0HS, United Kingdom
  • Novartis Investigative Site
    Manchester, M13 9NT, United Kingdom
  • Novartis Investigative Site
    Oxford, OX3 7LJ, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2012
First posted
Mar 20, 2012
Start
May 2012
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results first posted
Mar 3, 2015
Last update
Mar 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01558739
Responsible party
Sponsor
First posted
Mar 20, 2012
Start date
May 2012
Primary completion
Jan 2014
Completion
Jan 2014
Results posted
Mar 3, 2015
Last update
Mar 3, 2015

Study contacts

Study Director
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion